Cho Yunjoo, Kim Hyun-Soo
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Anticancer Res. 2024 Dec;44(12):5515-5524. doi: 10.21873/anticanres.17377.
BACKGROUND/AIM: Although preferentially expressed antigen in melanoma (PRAME) has been used as a diagnostic marker for malignant melanoma (MM), it is also expressed in various other malignancies. PRAME expression is rarely reported in female genital tumors. This study aimed to evaluate PRAME expression and its significance in gynecological malignancies.
We conducted PRAME immunostaining in 135 specimens, including 85 endometrial carcinomas (ECs), five uterine sarcomas (USs), 28 cervical carcinomas (CCs), and 17 ovarian carcinomas (OCs). PRAME immunoreactivity was evaluated using a semi-quantitative histoscore method.
PRAME was expressed in 82 (96.5%) ECs, 15 (88.2%) OCs, three (60.0%) USs, and eight (28.6%) CCs, with mean histoscores of 174.6, 108.9, 32.2, and 27.5, respectively. EC exhibited elevated PRAME expression levels compared to other tumors, with immunoreactivity being higher in endometrial endometrioid carcinoma (EEC) than that in other EC types. Grade 1 EEC exhibited higher PRAME expression levels than grade 2-3 EECs.
PRAME over-expression in gynecological tumors supports the notion that this marker should not be regarded as specific to MM alone. EC exhibited higher PRAME expression than CC and OC, and low-grade EEC displayed higher PRAME immunoreactivity than other EC types. Our findings suggest that PRAME immunostaining can be useful to distinguish EEC from ovarian endometrioid carcinoma and endocervical adenocarcinoma. PRAME over-expression can also help differentiate non-aggressive EC from aggressive EC.
背景/目的：尽管黑色素瘤优先表达抗原（PRAME）已被用作恶性黑色素瘤（MM）的诊断标志物，但它也在各种其他恶性肿瘤中表达。PRAME在女性生殖系统肿瘤中的表达鲜有报道。本研究旨在评估PRAME在妇科恶性肿瘤中的表达及其意义。
我们对135份标本进行了PRAME免疫染色，包括85例子宫内膜癌（EC）、5例子宫肉瘤（US）、28例宫颈癌（CC）和17例卵巢癌（OC）。采用半定量组织评分法评估PRAME免疫反应性。
PRAME在82例（96.5%）EC、15例（88.2%）OC、3例（60.0%）US和8例（28.6%）CC中表达，平均组织评分分别为174.6、108.9、32.2和27.5。与其他肿瘤相比，EC的PRAME表达水平升高，子宫内膜样腺癌（EEC）的免疫反应性高于其他EC类型。1级EEC的PRAME表达水平高于2-3级EEC。
PRAME在妇科肿瘤中的过表达支持了该标志物不应仅被视为MM特异性标志物的观点。EC的PRAME表达高于CC和OC，低级别EEC的PRAME免疫反应性高于其他EC类型。我们的研究结果表明，PRAME免疫染色有助于区分EEC与卵巢子宫内膜样癌和宫颈内膜腺癌。PRAME过表达也有助于区分非侵袭性EC与侵袭性EC。
